The biopharmaceutical industry
continues to be the most R&D-intensive industry in the U.S. economy, and PhRMA member companies are at the forefront. New data show PhRMA member companies invested $58.8 billion in research and development in 2015, up 10.3 percent from 2014.
For Cancer Survivors Like Matt, Today is a New Opportunity
Today, with new treatments in the pipeline for cancer, patients and families have more hope than ever before. Learn more about Matt, as he highlights how participation in a clinical trial and innovation from America’s biopharmaceutical research companies has kept him alive.
Medicines in Development for Rare Diseases
More than 560 medicines are in development for rare diseases, including therapies for multiple myeloma, cystic fibrosis and ALS, providing treatment options for patients that had few or no treatment options before.
Every Patient Has a Story
At 15 months old, Rhys was unusually tired. His pediatrician quickly figured out why: a tough combination of Type 1 diabetes and Celiac Disease. Fortunately, both can be managed with innovative medicines and diet. Today, Rhys is living the healthy, energetic childhood that every child deserves!